Cabozantinib

ArtNr	HY-13016-100mg
Hersteller	MedChem Express
CAS-Nr.	849217-68-1
Menge	100 mg
Quantity options	100 mg 10 mM/1 mL 10 mg 1 mg 200 mg 500 mg 50 mg 5 mg
Kategorie	Oncology Inhibitors & Compound Libraries Small Molecules By Organ Lung Cancer Breast Cancer Heart & Blood Cancer
Typ	Inhibitors
Specific against	other
Purity	99.96
Citations	[1]You WK, et al. VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer. Cancer Res, 2011, 71(14), 4758-4768.\|[2]Yakes FM, et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther, 2011, 10(12), 2298-2308.\|[3]Fuse MA, et al. Combination Therapy With c-Met and Src Inhibitors Induces Caspase-Dependent Apoptosis of Merlin-Deficient Schwann Cells and Suppresses Growth of Schwannoma Cells. Mol Cancer Ther. Mol Cancer Ther. 2017 Nov;16(11):2387-2398. Acta Pharmacol Sin. 2021 Jan;42(1):108-114.\|Adv Healthc Mater. 2023 Aug 21;e2302046.\|Am J Reprod Immunol. 2021 Mar;85(3):e13352.\|Antioxidants (Basel). 2021, 10(9), 1336.\|Biochem Biophys Rep. 2020 Jan 17;21:100726.\|Biochem Biophys Res Commun. 2024 Nov 19:734:150781.\|Biomaterials. 16 September 2022.\|Biomed Chromatogr. 2020 Aug;34(8):e4862.\|Biomed Chromatogr. 2023 May 15;e5685.\|Biomed Chromatogr. 2024 Jan 30:e5833.\|Biomedicines. 2020 Nov 28;8(12):547.\|bioRxiv. 2023 Apr 14.\|bioRxiv. 2024 November 03.\|BMC Biol. 2024 Oct 1;22(1):222.\|Br J Cancer. 2024 Jun 20.\|Cancer Discov. 2021 Jan;11(1):126-141.\|Cancer Lett. 2019 Apr 10;447:105-114.\|Cancers (Basel). 2024 Jan 8, 16(2), 269.\|Drug Des Devel Ther. 2018 Apr 30;12:1009-1017.\|Eur J Drug Metab Pharmacokinet. 2021 Jul 18;1-11.\|Exp Cell Res. 2020 Aug 1;393(1):112054.\|Front Oncol. 2022 Jul 7;12:915319.\|Fundam Clin Pharmacol. 2021 Feb 1.\|Int J Mol Sci. 2022 Sep 14;23(18):10677.\|Invest Ophthalmol Vis Sci. 2022 Dec 1;63(13):14.\|J Cell Biochem. 2020 Mar;121(3):2343-2353.\|J Med Chem. 2016 Jan 14;59(1):358-73.\|J Neurosci. 2020 Dec 9;40(50):9602-9616.\|J Pharm Anal. 2021 Jun 19.\|J Transl Med. 2023 Jan 9;21(1):9.\|Mediat Inflamm. 2020 Oct 24;2020:1649453.\|Mol Cancer Res. 2019 Feb;17(2):499-507. \|Mol Cancer Ther. 2017 Nov;16(11):2387-2398.\|Patent. US20170349880A1.\|Patent. US20220332731A1.\|PLoS One. 2017 Sep 25;12(9):e0185321. \|PLoS One. 2024 Nov 1;19(11):e0308647.\|React Kinet Mech Cat. 07 January 2022.\|Saudi Pharm J. 2023 Aug 24, 101756.\|Sci Rep. 2019 Nov 12;9(1):16600.\|Sci Transl Med. 2018 Jul 18;10(450):eaaq1093.\|Spectrochim Acta A Mol Biomol Spectrosc. 2016 Apr 15;159:199-208. \|Harvard Medical School LINCS LIBRARY\|Virology. 2023 Jun 21.
Smiles	O=C(C1(CC1)C(NC2=CC=C(F)C=C2)=O)NC3=CC=C(C=C3)OC4=C5C=C(OC)C(OC)=CC5=NC=C4
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	XL184,BMS-907351
Versandbedingung	Raumtemperatur
Lieferbar
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-Kinase/protease
Manufacturer - Targets	Apoptosis; c-Kit; c-Met/HGFR; FLT3; TAM Receptor; VEGFR
Shipping Temperature	Room Temperature
Storage Conditions	4°C (Powder, protect from light)
Molecular Weight	501.51
Product Description	Cabozantinib is a potent and orally active inhibitor of VEGFR2 and MET, with IC50 values of 0.035, and 1.3 nM, respectively. Cabozantinib displays strong inhibition of KIT, RET, AXL, TIE2, and FLT3 (IC50=4.6, 5.2, 7, 14.3, and 11.3 nM, respectively). Cabozantinib shows antiangiogenic activity. Cabozantinib disrupts tumor vasculature and promotes tumor and endothelial cell apoptosis[1][2].
Manufacturer - Research Area	Cancer
Solubility	DMSO: 25 mg/mL (ultrasonic)
Manufacturer - Pathway	Apoptosis; Protein Tyrosine Kinase/RTK
Isoform	Axl; Met; VEGFR1/Flt-1; VEGFR2/KDR/Flk-1; VEGFR3/Flt-4
Clinical information	Launched

Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.

Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.

Arbeitsanleitung (Data Sheet) anfordern

Produkt-Datenblatt anfordern

HY-13016-100mg-safety-datasheet.pdf